Evidence map›Paper›PMID 25884318›Full record

ArticleBMC neurology2015

Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies.

Julia Pakpoor, Olena O Seminog, Sreeram V Ramagopalan, Michael J Goldacre

Open access · goldAbstract read
In one paragraph

Article in BMC neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Update: Protective and risk factors for Parkinson disease.Parkinsonism & related disorders · 2024
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Julia PakpoorUnit of Health-Care Epidemiology, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK. julia.pakpoor@bnc.ox.ac.uk.
Olena O SeminogUnit of Health-Care Epidemiology, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK. olena.seminog@stx.ox.ac.uk.
Sreeram V RamagopalanDepartment of Physiology, Anatomy and Genetics and Medical Research Council Functional Genomics Unit, University of Oxford, Oxford, UK. sreeram@ramagopalan.net.
Michael J GoldacreUnit of Health-Care Epidemiology, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK. michael.goldacre@dph.ox.ac.uk.
University of Oxford · GBMedical Research Council · GB

Funding

Wellcome Trust 075491/Z/04
6 · The paper itself

Abstract

backgroundUric acid has antioxidant effects on neurons. Abnormally high levels of uric acid are, however, associated with gout. Previous studies have suggested that high levels of uric acid (and the presence of gout) may exert a protective effect against the risk of developing some neurological diseases. We aimed to investigate this hypothesis in a large database of hospital admissions in England.

methodsWe analysed a database of linked statistical records of hospital admissions and death registrations in England (1999-2012). A cohort of people with gout was constructed and followed for development of multiple sclerosis (MS), Parkinson's disease (PD) or motor neuron disease (MND). Then, conversely, cohorts of all people in the database with MS, PD or MND were constructed and followed for subsequent gout. Rate ratios (RRs) were determined, comparing these cohorts with people in a reference cohort.

resultsIn the gout cohort, we observed a modest elevation of the overall risk of subsequent MS, PD and MND (respectively, RR = 1.27 (95% confidence interval 1.03-1.55), 1.11 (1.05-1.17) and 1.28 (1.11-1.48) which was largely attributable to an increased risk observed in the early years after hospitalisation for gout. The increased risk of neurological disease did not remain after 5 years. In the cohorts of people with MS or PD, there was a significantly reduced risk of subsequent gout admission (RR = 0.79 (0.69-0.89) and 0.83 (0.79-0.87), respectively). This inverse association was sustained over time. There was also a reduced risk of MND following gout which only emerged more than five years following initial gout admission (RR at 5+ years 0.35 (0.15-0.68)).

conclusionsThis study investigated the epidemiological evidence for a protective role of high serum concentration of uric acid, for which we used gout as a proxy, in the aetiology of MS, PD or MND. Our observations do not support this hypothesis. However, when the order was reversed, and we retrospectively followed up patients with MS, PD and MND for a number of years, we found a statistically significant deficit of gout. This suggests that there is relationship between some aspects of these neurodegenerative diseases and metabolism of uric acid.

Indexed as

AdultAgedDatabases, FactualEnglandFemaleGoutHospitalizationHumansMaleMiddle AgedMotor Neuron DiseaseMultiple SclerosisParkinson DiseaseRetrospective StudiesRiskUric AcidUric Acid

Identifiers

PMID25884318
PMCPMC4355134
OpenAlexW2152375138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.